semaglutide and hfpef Efficacy safety of in patients with heart failure with preserved ejection fraction and obesity - Rehman - 2024 - Clinical Cardiology Semaglutide cardiovascular outcomes align more

To evaluate differential expression (DE) attributable to hypoxia, HIF1 and HIF2 (EPAS1) knockdown, a trivariate model was applied using limma

While no clinical trial has tested this combination, the anti-apoptotic and antioxidant effects of HIF-PHIs provide a strong mechanistic rationale for synergistic use with agents targeting erythrocyte apoptosis pathways (e.g., Bcl-xL upregulation or NIX inhibition)

These trials revealed that empagliflozin-treated patients with left ventricular ejection fraction 40% experienced a lower risk of cardiovascular death or hospitalization for heart failure regardless of the presence or absence of diabetes [26, 27]

471 KMT2 family mutations has been positively correlated with CRC progression